SecBot SecBot
8-K ·Filed Aug 6, 2026

XERS

Xeris Biopharma Holdings, Inc.
BULLISH
Impact 7/10
Horizonweeks Processed3mo ago SEC0001867096-26-000063
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The strong Q2 beat on revenue and Adjusted EBITDA, combined with the elimination of all 2028 Convertible Notes debt, removes a key overhang and strengthens the balance sheet. Traders should watch for the XP-8121 Phase 3 program webinar on September 9, 2026, which could serve as a major pipeline catalyst. The tightened guidance midpoint of $387.5M implies H2 revenue of ~$212M, requiring continued Recorlev momentum.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$7.36
T+0 close · Aug 6, 2026 · via day close
Latest settled
+45.52%
T+60 · $10.71
Vs SPY
+47.19%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 6 $7.36entry
  2. T+1 · 3mo ago +7.74%α +7.13% · $7.93
  3. T+5 · 3mo ago +13.18%α +11.97% · $8.33
  4. T+20 · 3mo ago +16.71%α +16.11% · $8.59
  5. T+60 · 18d ago +45.52%α +47.19% · $10.71
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Xeris Biopharma reported Q2 2026 total revenue of $92.1M (+29% YoY) and net product revenue of $91.0M (+34% YoY), driven by Recorlev's 81% growth to $56.8M. The GAAP net loss of $31.1M was largely due to a $31M non-cash charge from convertible note exchange agreements, while Adjusted EBITDA improved to $19.3M. The company tightened full-year 2026 revenue guidance to $385-390M, reflecting confidence in continued commercial momentum, and eliminated all remaining 2028 Convertible Notes debt through cash and stock exchanges, strengthening the balance sheet.

Key Financial Metrics

EPS
$0.00
est $0.00 · 0.0%
Revenue
$92.1M
est $90.1M · +2.2% · +28.7% YoY
Rating
beat
Guidance
$385M-$390M
maintained
Gross Margin
86%

Key Facts

  • Total revenue of $92.1M in Q2 2026, up 29% YoY from $71.5M
  • Net product revenue of $91.0M, up 34% YoY, driven by Recorlev (+81% to $56.8M)
  • GAAP net loss of $31.1M includes a ~$31M non-cash charge from convertible note exchange agreements
  • Adjusted EBITDA improved 54% to $19.3M from $12.5M in Q2 2025
  • Full-year 2026 revenue guidance tightened to $385-390M from $380-390M
  • All $33.5M of 2028 Convertible Notes eliminated via cash ($23M) and stock (~8.6M shares) exchanges in July 2026
  • Cash and cash equivalents increased to $121.7M at June 30, 2026 from $111.0M at Dec 31, 2025
  • Total shares outstanding rose to 182.3M at July 31, 2026 from 172.6M at April 30, 2026

Financial Impact

Revenue growth of $20.6M YoY (+29%); debt reduction of $33.5M (all 2028 Convertible Notes eliminated); Adjusted EBITDA improvement of $6.7M YoY

revenuedebtebitdadilution

Risk Factors

  • Share dilution from ~8.6M new shares issued in July 2026 for debt exchange
  • SGA expenses grew 37% YoY, outpacing revenue growth of 29%
  • XP-8121 Phase 3 trial initiation later in 2026 carries execution risk

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
85% bullish (13 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001867096-26-000063
Document: xers-20260806.htm0001867096-26-000063
Document: 0001867096-26-000063-index-headers.html0001867096-26-000063
Document: 0001867096-26-000063-index.html0001867096-26-000063
Document: 0001867096-26-000063.txt0001867096-26-000063
8-K Data (Synthetic)0001867096-26-000063

US Market Status

Market Closed · Opens in 5h 57m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 6, 2026